Cargando…

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

BACKGROUND: The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this disease, although some patients do not respond to therapy. Our goals were to investigate whether TUBB mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mesquita, Bárbara, Veiga, Isabel, Pereira, Deolinda, Tavares, Ana, Pinto, Isabel M, Pinto, Carla, Teixeira, Manuel R, Castedo, Sérgio
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1199587/ https://www.ncbi.nlm.nih.gov/pubmed/16095531 http://dx.doi.org/10.1186/1471-2407-5-101

Ejemplares similares

Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells.
por: Ranganathan, S., et al.
Publicado: (1998)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

Knockout of vasohibin‐2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer
por: Koyanagi, Takahiro, et al.
Publicado: (2021)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

The mammalian beta-tubulin repertoire: hematopoietic expression of a novel, heterologous beta-tubulin isotype
Publicado: (1986)

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy
por: Jung, Minkyu, et al.
Publicado: (2012)

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
por: Goyeneche, Alicia A, et al.
Publicado: (2012)

Piperlongumine Induces Apoptosis and Synergizes with Cisplatin or Paclitaxel in Human Ovarian Cancer Cells
por: Gong, Li-Hua, et al.
Publicado: (2014)

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
por: Ribeiro, J. R., et al.
Publicado: (2016)

Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells
por: van Haaften, Caroline, et al.
Publicado: (2015)

Sequence of a highly divergent beta tubulin gene reveals regional heterogeneity in the beta tubulin polypeptide
Publicado: (1984)

Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature
por: Serkies, Krystyna, et al.
Publicado: (2011)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
por: Tate, Shinichi, et al.
Publicado: (2021)

NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
por: Saldanha, Elroy, et al.
Publicado: (2022)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Rationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis
por: Das, Lalita, et al.
Publicado: (2012)

The Caenorhabditis elegans and Haemonchus contortus beta-tubulin genes cannot substitute for loss of the Saccharomyces cerevisiae beta-tubulin gene
por: Gibson, Sophia B, et al.
Publicado: (2021)

Paclitaxel and SN‐38 Overcome Cisplatin Resistance of Ovarian Cancer Cell Lines by Down‐regulating the Influx and Efflux System of Cisplatin
por: Komuro, Yuuki, et al.
Publicado: (2001)

A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis
por: Fruscio, R, et al.
Publicado: (2008)

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
por: Sherman-Baust, Cheryl A, et al.
Publicado: (2011)

Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein
por: Stordal, Britta, et al.
Publicado: (2012)

Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells
por: Szenajch, Jolanta, et al.
Publicado: (2020)

Class III β-Tubulin Counteracts the Ability of Paclitaxel to Inhibit Cell Migration
por: Ganguly, Anutosh, et al.
Publicado: (2011)

Dataset of GWAS-identified variants underlying venous thromboembolism susceptibility and linkage to cancer aggressiveness
por: Tavares, Valéria, et al.
Publicado: (2020)

Cancer Cells Acquire Mitotic Drug Resistance Properties Through Beta I-Tubulin Mutations and Alterations in the Expression of Beta-Tubulin Isotypes
por: Cheung, Chun Hei Antonio, et al.
Publicado: (2010)

Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2
por: Barbosa, Ana, et al.
Publicado: (2020)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity
por: Gamarra-Luques, Carlos D, et al.
Publicado: (2014)

MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1
por: Sun, Kai-Xuan, et al.
Publicado: (2015)

Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study
por: Coccolini, Federico, et al.
Publicado: (2015)

Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells
por: Gao, Jianwen, et al.
Publicado: (2021)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

Two Drosophila beta tubulin isoforms are not functionally equivalent
Publicado: (1990)

Differential utilization of beta-tubulin isotypes in differentiating neurites
Publicado: (1989)

Molecular docking and dynamic simulations of benzimidazoles with beta-tubulins
por: Rao, Chennu Maruthi Malya Prasada, et al.
Publicado: (2021)

Soluble tubulin is significantly enriched at mitotic centrosomes
por: Baumgart, Johannes, et al.
Publicado: (2019)

MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease
por: Pinto, C, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_sjj0ppsnep73f5vrr7h878ndfs